A5059838967- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Polyomavirus and related diseases
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Pancreatic function and diabetes
- Transplantation: Methods and Outcomes
- Cytomegalovirus and herpesvirus research
- Mesenchymal stem cell research
- Organ Transplantation Techniques and Outcomes
- Lymphoma Diagnosis and Treatment
- Xenotransplantation and immune response
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Virus-based gene therapy research
- Blood groups and transfusion
- Mycobacterium research and diagnosis
Penn State Milton S. Hershey Medical Center
2015-2024
Hershey (United States)
2007-2024
Pennsylvania State University
2009-2023
Merck & Co., Inc., Rahway, NJ, USA (United States)
2018
Beth Israel Deaconess Medical Center
2017
University Medical Center
2017
Dana-Farber Cancer Institute
2017
University of Kansas Medical Center
2017
Cancer Institute (WIA)
2016
University of Pittsburgh Medical Center
1993-1997
Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free Patients and Methods Two hundred fifty-four patients 18 65 years age acute leukemia or myelodysplastic...
T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is a recently identified coinhibitory receptor. In this study, we aimed to determine the clinical impact of TIGIT in patients with acute myelogenous leukemia (AML) dissect role pathogenesis progression.TIGIT expression on T cells from peripheral blood collected AML was examined by flow cytometry. The correlation outcomes, including rate complete remission relapse post-allogeneic stem cell...
Treatment of acute myeloid leukemia (AML) remains challenging. Enhancement anti-tumor responses by blocking negative immune regulators is a promising strategy for novel effective therapeutics. V-domain Ig suppressor T-cell activation (VISTA) recently defined regulator mediating evasion in cancer. To investigate the effect VISTA on anti-leukemia response AML, we initiated study using clinical samples collected from AML patients. Here report that highly expressed myeloid-derived cells (MDSCs)...
Abstract Prognosis of leukemia relapse post allogeneic stem cell transplantation (alloSCT) is poor and effective new treatments are urgently needed. T cells pivotal in eradicating through a graft versus (GVL) effect considered failure GVL. T-cell exhaustion state dysfunction mediated by inhibitory molecules including programmed death protein 1 (PD-1) immunoglobulin domain mucin 3 (TIM-3). To evaluate whether pathways involved alloSCT, we performed phenotypic functional studies on from...
Abstract Bone marrow cells have the capacity to contribute distant organs. We show that also contributes epithelial neoplasias of small bowel, colon, and lung, but not skin. In particular, found in patients after hematopoietic cell transplantations demonstrate human incorporates into by adopting phenotype surrounding neoplastic environment. To more rigorously evaluate contribution cancer, we employed mouse models intestinal lung neoplasias, which revealed specifically stem its progeny...
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) programmed death protein 1 (PD-1) are important receptors that associate with exhaustion in acute myeloid leukemia (AML). In this study, we aimed to determine the underlying transcriptional mechanisms regulating these pathways. Specifically, investigated role of transcription factor B lymphocyte-induced maturation (Blimp-1) response regulation TIGIT PD-1 AML. Peripheral blood samples collected from...
Acute myeloid leukemia (AML) is a devastating blood cancer with poor prognosis. Immunotherapy targeting inhibitory pathways to unleash the antileukemia T-cell response promising strategy for treatment of leukemia, but we must first understand underlying molecular mechanisms. Eomesodermin (Eomes) and T-bet are both T-box transcription factors that regulate CD8+ responses in context-specific manner. Here, examined role these immunity AML patients. We report frequency Eomes+T-betlow T cells...
Highlights•Late fatal infection (LFI) contributed to one-third of the deaths in both adult and pediatric hematopoietic cell transplantation (HCT) recipients surviving 2 years post-HCT.•In adults age ≥20 years, receipt matched unrelated donor (MUD) or mismatched (MMUD) HCT male sex were associated with an increased risk LFI.•In subjects, ≥10 MUD MMUD HCT, inherited abnormalities erythrocyte function LFI.ABSTRACTWe analyzed late infections (LFIs) allogeneic stem reported Center for...
Relapse after high-dose chemotherapy is the main cause of therapeutic failure in patients with metastatic breast cancer. Adoptive immunotherapy interleukin-2 (IL-2) plus activated natural killer cells may eliminate residual disease without excessive toxicity. The authors sought to determine if immediately transplantation would affect engraftment and toxicity associated transplantation. Fifteen consecutive cancer were allocated three cohorts. Cohort 1 (five patients) received...
Preclinical data demonstrated that combining an anti-programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) provided enhanced antitumor activity no significant toxicities, suggesting this combination may be potential therapeutic option. The multicohort, phase KEYNOTE-155 study evaluated the safety and of PD-1 pembrolizumab plus CDK9 dinaciclib in patients relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) multiple...
To improve the outcome of relapsed/refractory acute myeloid leukemia (AML), a randomized phase II trial three novel regimens was conducted. Ninety patients were enrolled and in first relapse or refractory to induction/re‐induction chemotherapy. They following regimens: carboplatin‐topotecan (CT), each by continuous infusion for 5 days; alvocidib (formerly flavopiridol), cytarabine, mitoxantrone (FLAM) timed sequential regimen; sirolimus combined with mitoxantrone, etoposide, cytarabine...
Abstract Background Bacterial prophylaxis with a fluoroquinolone (FQ) during autologous stem cell transplant (ASCT) is common, although not standardized among centers. The addition of doxycycline (doxy) to FQ was previously linked reduced neutropenic fever and bacteremia in multiple myeloma (MM) patients undergoing ASCT several confounders were present. We compared the incidence between MM variably receiving alone FQ‐doxy ASCT. Methods Systematic retrospective chart review who underwent...
On the basis of observations in patients with long-term (28-30 years) renal allograft survival, all whom had evidence systemic microchimerism, we began a program combined simultaneous kidney/bone marrow transplantation. Between 12/14/92, and 10/31/94, 36 kidney transplant recipients received 3-5 x 10(8) unmodified bone cells/kg; 6 also pancreatic islets, 7 pancreas. The mean recipient age was 39.0 +/- 10.8 years, donor 31.8 16.1 years; cold ischemia time 23.0 9.1 hr. Twenty control kidneys...
We recently conducted a randomized double-blind study in which we demonstrated that moderate/severe chronic graft-versus-host disease (cGVHD) but not cGVHD-free survival was reduced patients receiving anti-T lymphocyte globulin (ATLG) versus placebo. In companion performed immunophenotypic analysis to determine the impact of ATLG on immune reconstitution (IR) and correlate IR with clinical outcomes. The (n = 254) included (aged 18 65 years) who underwent myeloablative transplants for acute...
Recent studies on patients who have maintained stable hepatic and renal allograft function for 10–28 years revealed systemic microchimerism in all (1, 2). With the belief that this is essential mechanism of acceptance, we sought to augment spontaneous chimerism newly transplanted recipients, began a program combined simultaneous kidney/bone marrow transplantation without pretransplant radiation or other cytoreduction therapy (3). Postoperative immunosuppression was with FK506 prednisone,...
SummarySix human haematopoietic cell lines, five of leukaemic origin, including cells with myeloid, lymphoid and undifferentiated phenotype have been studied respect to radiation response. The intrinsic radiosensitivity the varied widely, D0s ranging from 0·53 1·39 Gy. Five lines showed some capacity accumulate sublethal damage; in three these, enhanced survival was demonstrated split-dose experiments. One line (HL-60) anomalous that although little accumulation damage demonstrable, by...